Asymchem is expanding its API manufacturing facilities to provide clients with peptide and oligonucleotide products for R&D needs in this expanding therapeutic area.   The initial oligonucleotide commercial-scale production site will be 62,160 sq.-ft. as an expansion of Asymchem’s existing small molecule API facility in Tianjin, China. The GMP facility will accommodate gram to ton production scales. Phase 1 of the facility is scheduled to be fully operational in 3Q22 and will include...